Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Carolina Cimminiello"'
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 11, Iss 7, Pp XD06-XD08 (2017)
The most frequently reported skin tumours during treatment with targeted therapies for BRAF (B type Rapidly Accelerated Fibrosarcoma kinase) mutated metastatic melanoma are squamous cell carcinomas (SCCs). Basal cell carcinomas (BCCs) have been desc
Externí odkaz:
https://doaj.org/article/09f3690445c44ba2bdb48b23c6961704
Autor:
Lorenza Di Guardo, Viviana Vallacchi, Michele Del Vecchio, Monica Rodolfo, Filippo de Braud, Giovanni Randon, Mara Cossa, Marta Bini, Roberto Patuzzo, Licia Rivoltini, Gianfrancesco Gallino, Ilaria Mattavelli, Andrea Maurichi, Mario Santinami, Barbara Valeri, Carolina Cimminiello, Roberta Ruggeri, Giovanni Fucà, Alessandra Raimondi, Martina Angi, Francesca Corti
Publikováno v:
The Oncologist
Background Outcomes of patients with metastatic melanoma discontinuing BRAF‐targeted therapy for cumulative toxicity after sustained response are unknown. Materials and Methods This retrospective case series analysis conducted at a single Cancer Ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fb6ee4eda7bbea038066dc6d0be7760
https://doi.org/10.1002/onco.13926
https://doi.org/10.1002/onco.13926
Autor:
Carolina Cimminiello, Lorenza Di Guardo, Massimo Di Nicola, Laura Mazzeo, Marta Del Vecchio, Filippo de Braud, Marta Bini, Giovanni Randon, Teresa Beninato, Michele Del Vecchio, Giulia Apollonio, Claudia Lauria Pantano, Giovanni Fucà, Ilaria Bisogno
Publikováno v:
Targeted Oncology. 16:529-536
Since a non-negligible fraction of patients with metastatic melanoma does not experience long-term disease control, even with immunotherapy and targeted therapy, new biomarkers for patient stratification and treatment tailoring are needed in this set
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c466579f8b4033f6d95a5aa003dbab4b
https://doi.org/10.1007/s11523-021-00819-0
https://doi.org/10.1007/s11523-021-00819-0
Autor:
Bruno Giometto, Carolina Cimminiello, Paola Bini, Enrico Marchioni, Enrico Alfonsi, Marco Zoccarato, Eugenia Rota, Veronica Villani, Edvina Galiè, Anna Pichiecchio, Michele Del Vecchio, Alberto Vogrig, Roberta Rudà, Luca Diamanti, Valentina Poretto, Alberto Picca, Francesco Bruno, Mariarosaria Valente, Matteo Gastaldi
Background: Neurological immune-related adverse events (nirAEs) are rare toxicities of immune-checkpoint inhibitors (ICI). With the increase of ICI oncological indications, their incidence is growing. Their recognition and management remain neverthel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f94a48740431f9b7c28dc348345b3646
https://link.springer.com/article/10.1007/s10072-021-05561-z
https://link.springer.com/article/10.1007/s10072-021-05561-z
Autor:
Irene Vetrano, Lorenza Di Guardo, Carolina Cimminiello, Teresa Beninato, Francesco Nesa, Michele Del Vecchio, Giovanni Fucà, Barbara Valeri
Publikováno v:
Melanoma Research. 31:178-180
Immune-checkpoint inhibitors (ICIs) exposed the oncology community to novel immune-related adverse events (irAEs). Here, we report on a retrospective analysis of patients with melanoma who developed an ICI-related, unilateral, acute and peripheral fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a943db47bb3504e5b6e97af6c8da21dd
https://doi.org/10.1097/cmr.0000000000000715
https://doi.org/10.1097/cmr.0000000000000715
Autor:
Elena Tolomio, Lorenza Di Guardo, Michele Del Vecchio, Giovanni Randon, Michele Prisciandaro, Carolina Cimminiello, Alice Indini, Filippo de Braud
Publikováno v:
Melanoma Research. 29:289-294
Pembrolizumab is an anti-programmed cell death-1 monoclonal antibody, currently representing the first-line treatment for advanced melanoma. Apart from registration trials, there is a paucity of data on its effectiveness and safety in a real-world se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::242b2031d015883aa11b8be9429a145e
https://doi.org/10.1097/cmr.0000000000000539
https://doi.org/10.1097/cmr.0000000000000539
Autor:
Michele Prisciandaro, Giovanni Randon, Filippo de Braud, Lorenza Di Guardo, Michele Del Vecchio, Alice Indini, Carolina Cimminiello
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 145:511-521
Therapeutic chances for metastatic melanoma have consistently changed over the last years with the advent of antibodies targeting the programmed cell death protein-1 (PD-1). Onset of immune-related adverse events (irAEs) during treatment can be a sou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::366a3d7436a56d76a5ecda05de0d655a
https://doi.org/10.1007/s00432-018-2819-x
https://doi.org/10.1007/s00432-018-2819-x
Autor:
Carolina Cimminiello, Mario Mandalà, Lorenza Di Guardo, Paola Queirolo, Ignazio Stanganelli, Enrica Teresa Tanda, Elena Marra, Alfredo Falcone, Pietro Quaglino, Gerardo Botti, Francesco Spagnolo, Anna Maria Di Giacomo, Francesco De Rosa, Giuseppe Palmieri, Vanna Chiarion Sileni, Riccardo Marconcini, Luigia Stefania Stucci, Stefano Cavalieri, Corrado Caracò, L. Orgiano, Simone Ribero, Laura Spano, Virginia Picasso
Publikováno v:
Oncotarget
// Riccardo Marconcini 1 , Francesco Spagnolo 2 , Luigia Stefania Stucci 3 , Simone Ribero 4 , Elena Marra 4 , Francesco De Rosa 5 , Virginia Picasso 2 , Lorenza Di Guardo 6 , Carolina Cimminiello 6 , Stefano Cavalieri 6 , Laura Orgiano 7 , Enrica Ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa3b411a1565312df88f933099227502
https://doi.org/10.18632/oncotarget.23746
https://doi.org/10.18632/oncotarget.23746
Autor:
Carolina Cimminiello, Alice Indini, Michele Prisciandaro, Filippo de Braud, Michele Del Vecchio, Lorenza Di Guardo, Giovanni Randon
Publikováno v:
Tumori. 105(6)
Background: Prognosis of patients with metastatic melanoma has improved due to the advent of antibodies targeting the programmed cell death protein-1 (PD-1). However, therapeutic outcomes from anti-PD-1 therapy widely differ among patients. Biomarker
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f7dbe3b3c3851f8b3190fd2234d6e77
https://pubmed.ncbi.nlm.nih.gov/31446882
https://pubmed.ncbi.nlm.nih.gov/31446882
OBJECTIVE Prognosis of patients with metastatic melanoma has dramatically improved over recent years because of the advent of antibodies targeting programmed cell death protein-1 (PD1). However, the response rate is ~40% and baseline biomarkers for t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fc5b6f8462c86dc8d9992b8e903ab6f
http://hdl.handle.net/2434/659811
http://hdl.handle.net/2434/659811